Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases

被引：0
作者：
Xiaojing Yang
Hanru Ren
Yi Xu
Xue Peng
Wenxi Yu
Zan Shen
机构：
[1] Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Department of Oncology
[2] Shanghai Pudong Hospital,Department of Orthopedics, Pudong Medical Center
[3] Fudan University,Department of Radiation Oncology
[4] Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Department of Breast Surgery
[5] Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,undefined
来源：
European Journal of Medical Research | / 28卷
关键词：
Breast cancer; Human epidermal growth factor receptor 2; Brain metastasis; Radiation therapy; Targeted therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiotherapy for brain metastases has also become an important issue of clinical concern. It remained unclear how to achieve the balance of efficacy and toxicity with the application of new radiotherapy techniques and new targeted therapy drugs. This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases.
引用
收藏
相关论文
共 996 条
  • [11] Lah TT(2000)Molecular portraits of human breast tumours Nature 406 747-1747
  • [12] Novak M(2011)Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736-1205
  • [13] Breznik B(2017)11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Lancet 389 1195-4843
  • [14] Wilson TG(2011)Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER Clin Cancer Res 17 4834-900
  • [15] Robinson T(2009)Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients Br J Cancer 100 894-343
  • [16] Macfarlane C(2020)Beyond an Updated Graded Prognostic Assessment (Breast GPA): a prognostic index and trends in treatment and survival in breast cancer brain metastases from 1985 to today Int J Radiat Oncol Biol Phys 107 334-365
  • [17] Spencer T(2008)Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival J Neurooncol 88 359-7062
  • [18] Herbert C(2017)Outcome evaluation of HER2 breast cancer patients with limited brain metastasis Anticancer Res 37 7057-431
  • [19] Wade L(2021)Concurrent radiation therapy and dual HER2 blockade in breast cancer: assessment of toxicity Cancer Radiother 25 424-62
  • [20] Reed H(2022)Radiobiology of stereotactic radiotherapy Rep Pract Oncol Radiother 27 57-50
12345678910